Miniatura

Fitxers

698641.pdf (1.52 MB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2019-08-05

Llicència de publicació

cc-by-nc-nd (c) AGA Institute, 2019
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/173530

Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.cgh.2019.07.055

Resum

Background & aims: We performed a randomized trial to determine whether albumin should be administered to patients with infections unrelated to spontaneous bacterial peritonitis (SBP). Methods: We performed a multicenter, open-label trial in which 118 patients with cirrhosis, non-SBP infections, and additional risk factors for poor outcome were randomly assigned to receive antibiotics plus albumin (study group; n = 61) or antibiotics alone (control group; n = 57). The primary outcome was in-hospital mortality; secondary outcomes were effect of albumin on disease course. Results: There were no significant differences at baseline between groups in results from standard laboratory tests, serum markers of inflammation, circulatory dysfunction, or liver severity scores. However, the combined prevalence of acute on chronic liver failure (ACLF) and kidney dysfunction was significantly higher in the study group (44.3% vs 24.6% in the control group; P = .02), indicating greater baseline overall severity. There was no significant difference in the primary outcome between groups (13.1% in the study group vs 10.5% in the control group; P = .66). Circulatory and renal functions improved in only the study group. A significantly higher proportion of patients in the study group had resolution of ACLF (82.3% vs 33.3% in the control group; P = .03). A significantly lower proportion of patients in the study group developed nosocomial infections (6.6% vs 24.6% in the control group; P = .007). Conclusions: In a randomized trial of patients with advanced cirrhosis and non-SBP infections, in-hospital mortality was similar between those who received albumin plus antibiotics vs those who received only antibiotics (controls). However, patients given albumin were sicker at baseline and, during the follow-up period, a higher proportion had ACLF resolution and a lower proportion had nosocomial infections. ClinicalTrials.gov no: NCT02034279.

Matèries

Agents antiinfecciosos, Albúmines, Malalties infeccioses, Cirrosi hepàtica

Matèries (anglès)

Anti-infective agents, Albumins, Communicable diseases, Hepatic cirrhosis

Citació

Col·leccions

Articles publicats en revistes (Biomedicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

FERNÁNDEZ GÓMEZ, Javier, ANGELI, Paolo, TREBICKA, Jonel, MERLI, Manuela, GUSTOT, Thierry, ALESSANDRIA, Carlo, AAGAARD, Niels kristian, GOTTARDI, Andrea de, WELZEL, Tania mara, GERBES, Alexander l., SORIANO PASTOR, Germán, VARGAS, Víctor, ALBILLOS, Agustín, SALERNO, Francesco, DURAND, François, BAÑARES, Rafael, STAUBER, Rudolf e., PRADO, Verónica, ARTEAGA LÓPEZ, Mireya, HERNÁNDEZ TEJERO, María, AZIZ, Fátima, MORANDO, Filippo, JANSEN, Christian, LATTANZI, Barbara, MORENO, Christophe, CAMPION, Daniela, GRONBAEK, Henning, GARCÍA, Rita, SÁNCHEZ, Cristina, GARCÍA, Elisabet, AMORÓS, Àlex, PAVESI, Marco, CLÀRIA I ENRICH, Joan, MOREAU, Richard, ARROYO, Vicente. Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis. _Clinical Gastroenterology and Hepatology_. 2019. Vol. 18, núm. 4, pàgs. 963-973. [consulta: 23 de gener de 2026]. ISSN: 1542-3565. [Disponible a: https://hdl.handle.net/2445/173530]

Exportar metadades

JSON - METS

Compartir registre